{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-023200","form_type":"8-K","ticker":"LTRN","cik":"0001763950","company_name":"Lantern Pharma Inc.","filed_at":"2026-05-14T21:26:31+00:00","discovered_at":"2026-05-14T21:28:00.294463+00:00","generated_at":"2026-05-14T21:28:12.970435+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lantern Pharma raises $4.4M through registered direct offering; plans to spin out AI platform","bullets":["Offered 2,135,923 shares at $2.06/share (or pre-funded warrants) plus unregistered warrants for equal shares.","Unregistered warrants have exercise price $2.27, exercisable after 6 months, expire 5 years from initial exercise.","Up to additional $4.85M gross proceeds if warrants fully exercised; no assurance of exercise.","Company plans to separate AI platform withZeta.ai into independent entity; may become publicly listed.","Suspended ATM sales under July 2025 agreement with ThinkEquity; agreement remains in effect."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-023200","json":"https://secwatch.observer/filing/0001493152-26-023200.json","markdown":"https://secwatch.observer/filing/0001493152-26-023200.md","text":"https://secwatch.observer/filing/0001493152-26-023200.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/0001493152-26-023200-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-14T21:28:12.970435+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d8789e5c719ff8e9e700e25b88b98e3930ecb630","claim":"Lantern Pharma Inc. entered into Purchase Agreement with institutional investors valued at approximately $4.4 million (effective 2026-05-12).","evidence_excerpt":"On May 12, 2026, Lantern Pharma Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with institutional investors","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1763950/000149315226023200/0001493152-26-023200-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"equity purchase"},{"label":"Counterparty","value":"institutional investors"},{"label":"Value","value":"approximately $4.4 million"},{"label":"Effective","value":"2026-05-12"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}